Lidocaine and monoethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration

被引:8
作者
Muñoz, AE
Miguez, C
Rubio, M
Bartellini, M
Levi, D
Podestá, A
Niselman, V
Terg, R
机构
[1] Univ Salvador, Sch Med, Hosp Dr Bonorino Udaondo, Unidad Hepatol, RA-1264 Buenos Aires, DF, Argentina
[2] CONICET, Inst Invest farmacol, RA-1033 Buenos Aires, DF, Argentina
关键词
drug metabolism; liver function test; hepatic pharmacology; monoethylglycinexylidide; lidocaine;
D O I
10.1023/A:1026630313038
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Our aim was to compare standard liver function tests (serum bilirubin, serum albumin and prothrombin concentration), with lidocaine and monoethylglycinexylidide pharmacokinetic parameters, after oral lidocaine administration, to assess hepatic function of cirrhotic individuals. Twenty-one consecutive cirrhotic patients, nine consecutive acute hepatitis patients, and nine healthy individuals received oral lidocaine. Lidocaine and monoethylglycinexylidide serum concentrations were determined by the TDx system. Cirrhotic patients had higher lidocaine and lower monoethylglycinexylidide serum concentrations and differences in its pharmacokinetic variables, compared to control and hepatitis groups (P < 0.05). Sensitivity of lidocaine serum determinations (100%) was greater than sensitivity of serum bilirubin (57%), serum albumin (62%), and prothrombin concentrations (43%) and monoethylglycinexylidide serum concentrations (57%) in differentiating cirrhotic individuals from controls. In conclusion, after oral administration, lidocaine and monoethylglycinexylidide pharmacokinetic parameters are significantly altered in cirrhotic patients compared to normal and acute hepatitis subjects. Lidocaine pharmacokinetic parameters would be better than those of monoethylglycinexylidide and standard liver function tests in the evaluation of liver function of cirrhotic patients.
引用
收藏
页码:789 / 795
页数:7
相关论文
共 51 条
[1]   MONOETHYLGLICINEXYLIDIDE TEST - A PROGNOSTIC INDICATOR OF SURVIVAL IN CIRRHOSIS [J].
ARRIGONI, A ;
GINDRO, T ;
AIMO, G ;
CAPPELLO, N ;
MELONI, A ;
BENEDETTI, P ;
MOLINO, GP ;
VERME, G ;
RIZZETTO, M .
HEPATOLOGY, 1994, 20 (02) :383-387
[2]   LIDOCAINE METABOLISM IN HUMAN-LIVER MICROSOMES BY CYTOCHROME-P450IIIA4 [J].
BARGETZI, MJ ;
AOYAMA, T ;
GONZALEZ, FJ ;
MEYER, UA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (05) :521-527
[3]  
BARSTOW L, 1990, PHARMACOTHERAPY, V10, P280
[4]   PHARMACOKINETICS OF LIDOCAINE AND ITS DE-ETHYLATED METABOLITE - DOSE AND TIME DEPENDENCY STUDIES IN MAN [J].
BENNETT, PN ;
AARONS, LJ ;
BENDING, MR ;
STEINER, JA ;
ROWLAND, M .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1982, 10 (03) :265-281
[5]   QUANTITATIVE ASSESSMENT OF DERANGED HEPATIC-FUNCTION - A MISSED OPPORTUNITY [J].
BIRCHER, J .
SEMINARS IN LIVER DISEASE, 1983, 3 (04) :275-284
[6]  
BOYES RN, 1971, CLIN PHARMACOL THER, V12, P105
[7]  
BOYES RN, 1970, J PHARMACOL EXP THER, V174, P1
[8]  
BRANCH R A, 1976, Clinical Pharmacokinetics, V1, P264
[9]  
BURDELSKI M, 1988, TRANSPLANT P, V20, P591
[10]  
BURDELSKI M, 1987, TRANSPLANT P, V19, P3838